Mochida Pharmaceutical Co.,Ltd. (4534.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 3,340.00

From 52W high−16.02%

Volume51600.00

Market capJPY 118.05B

P/E (TTM)12.8x

P/S (TTM)1.0x

Div yield2.40%

Key dataSep 18, 2026

Open

JPY 3,340.00

From 52W high

−16.02%

Volume

51600.00

Market cap

JPY 118.05B

ValuationView details →

P/E (Fwd)

14.3x

EV/EBITDA

7.1x

P/E (TTM)

12.8x

RSI (14)

57.6

MomentumView details →

1D Return

+1.83%

YTD Return

−6.65%

ValuationView details →

P/E (Fwd)

14.3x

P/E (TTM)

12.8x

EV/EBITDA

7.1x

EV/Sales

0.8x

P/S (TTM)

1.0x

P/B (TTM)

0.8x

ProfitabilityView details →

Gross Margin

48.06%

Net Margin

5.74%

EBITDA Margin

9.89%

ROE (TTM)

4.67%

ROA (TTM)

3.52%

Asset Turnover

0.64x

GrowthView details →

Revenue YoY

+6.18%

EPS YoY

+12.53%

FCF YoY

—

Revenue CAGR 3Y

−1.54%

EPS CAGR 3Y

−16.70%

EBITDA YoY

—

MomentumView details →

1D Return

+1.83%

YTD Return

−6.65%

1Y Return

+1.38%

RSI (14)

57.6

vs 50D SMA

+2.87%

vs 200D SMA

−3.46%

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

4.01x

Quick Ratio

3.33x

Div Yield

2.40%

Div Rate

—

Div Growth 1Y

+0.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

108.88B

Net Income (TTM)

5.50B

Op. CF (TTM)

—

Next earningsOct 30, 2026 →

Latest newsMore news →

Mochida Pharmaceutical succeeded the manufacturing and marketing approval for the gout and hyperuricemia treatment 'Topirolic' from Fuji Pharmaceutical and acquired related assets including intellectual property rights.32d ago

Similar companies

Nxera Pharma Co.,Ltd.4565.T PeptiDream Inc.4587.T KAKEN PHARMACEUTICAL CO.,LTD.4521.T ZERIA PHARMACEUTICAL CO.,LTD.4559.T GNI Group Ltd.2160.T Oncolys BioPharma Inc.4588.T Find similar companies →

Latest newsMore news →

Mochida Pharmaceutical succeeded the manufacturing and marketing approval for the gout and hyperuricemia treatment 'Topirolic' from Fuji Pharmaceutical and acquired related assets including intellectual property rights.32d ago